LYR-210 A NEW THERAPEUTIC SOLUTION FOR CRS

Lyra’s lead product candidate, LYR-210, is in Phase 2 clinical development for the treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the nasal passages. LYR-210 is a proprietary therapeutic that delivers a custom long-acting formulation of mometasone fuorate, a proven steroid, deep into the sinonasal tissue.

LYR-210 is the only treatment offering up to 6 months of local therapy at the site of disease from a single administration for the treatment of CRS.

LYR-210’s unique therapeutic properties enable it to address the challenges of CRS

Adaptable mesh design conforms to nasal cavity anatomy and is administered in a physician’s office.
Long-acting medication provides anti-inflammatory therapy for up to 6 months.
Localized effect directly on diseased tissues that are difficult to access with conventional approaches.

HERE’S HOW LYR-210 WORKS

BEFORE TREATMENT

CRS symptoms include nasal congestion and discharge, facial pain and pressure, loss of sense of smell and sleep difficulties.

AFTER LYR-210 TREATMENT

Inflammation subsides as anti-inflammatory medicine is continually released directly to tissues. The mesh scaffold continuously expands to stay in place as inflammation recedes, for months of treatment. Nasal congestion and other CRS symptoms improve.

LOCAL IMPACT AT SITE OF CRS

LYR-210 enables therapeutic action at the site of CRS inflammation in the sinonasal passages, offering an alternative to conventional approaches:

  • Topical steroid sprays are not effective at penetrating deep into sinonasal passages or maintaining a therapeutic concentration over time
  • Surgical interventions do not directly address underlying inflammation

LYR-210 ON CLINICAL PATH FOR CRS

Clinical results evaluating LYR-210 in CRS patients in a Phase 1 clinical study have shown LYR-210 to be safe and well-tolerated and demonstrated significant improvements in clinical outcomes in patients with CRS.

For a summary of the results from the Phase 1 clinical study of LYR-210 in CRS, please see the announcement of the clinical data at the American Rhinologic Society Annual Meeting in October 2018.

The Phase 1 results for LYR-210 have been published:
Douglas RG, Psaltis AJ, Rimmer J, Kuruvilla T, Cervin A, and Kuang Y. Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis. International Forum of Allergy & Rhinology, Vol. 9, No. 4, April 2019.

Back to Top